GailLynn(Shaw)WrightMDFACP, FCCP

Oncology • Hudson, FL

Breast Cancer

Florida Cancer Specialists & Research Institute

Join to view full profile

Dr. Wright is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wright's full profile

Already have an account?

Office
7651 Medical Dr
Hudson, FL 34667
Phone+1 727-868-9208

Fax+1 727-868-6420

Summary

Gail (Shaw) Wright, MD, is a seasoned oncologist based in Trinity, FL with a focus on breast cancer. She conducted her fellowship in Hematology and Medical Oncology at the National Institutes of Health Clinical Center and has been associated with HCA Bayonet Point Hospital and HCA Trinity Hospital since 2004. She has significant experience in treating breast and lung cancer. Dr. Wright has an extensive portfolio of publications in prestigious journals like Clinical Cancer Research, Gynecologic Oncology, and Annals of Oncology, covering a range of topics mainly concerning treatments for breast cancer. She has been involved in several clinical trials to further the understanding of breast cancer treatments. She received CMS Meaningful Use Stage 1 Certification from OncoEMR, Altos Solutions, Inc. between 2012 and 2014.

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1986 - 1989
Duke University HospitalResidency, Internal Medicine, 1984 - 1986
University of North Carolina HospitalsInternship, Internal Medicine, 1983 - 1984
University of North Carolina at Chapel Hill School of MedicineClass of 1983

Certifications & Licensure

FL State Medical License 1996 - 2027
GA State Medical License 1999 - 2023
SC State Medical License 2001 - 2004
NC State Medical License 1984 - 2000
VA State Medical License 1987 - 2000
MD State Medical License 1988 - 1995
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2014

Clinical Trials

Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index Start of enrollment: 2013 Apr 01
Completed
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread Start of enrollment: 2014 Jun 10
Completed
Phase 2
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer Start of enrollment: 2017 Jun 20
Completed
Phase 2
Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC Start of enrollment: 2017 Dec 21
Terminated
Phase 3
G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer Start of enrollment: 2018 May 09
Completed
Phase 1
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC Start of enrollment: 2019 Jul 09
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

30 citations
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Pha...
Hope S Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano
Journal of Clinical Oncology. 2023-01-10
31 citations
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with be...
Melissa M Hardesty, Thomas C Krivak, Gail S Wright, Erika Hamilton, Evelyn L Fleming
Gynecologic Oncology. 2022-08-01
86 citations
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow...
C E Geyer, W M Sikov, J Huober, H S Rugo, N Wolmark
Annals of Oncology. 2022-04-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Association for Cancer Research - AACR
Member
American College of Physicians - ACP
Fellow
American College of Chest Physicians - ACCP
Fellow
International Association for the Study of Lung Cancer - IASLC
Member

External Links

ABIMhttps://www.abim.org/verify-physician.aspx?type=id&id=107452